HIV Infections Clinical Trial
Official title:
A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection
This is a phase I/II study to determine the safety and tolerance of the protease inhibitor
indinavir (MK-0639), alone and then in combination with HIV reverse transcriptase inhibitor
therapy in children with HIV infection. Indinavir sulfate (the capsule formulation) has been
shown to have potent antiviral activity and an acceptable safety profile in adults.
HIV-infected children who have not received prior antiretroviral therapy, and children who
have become refractory to prior therapy, or who have experienced toxicity to prior therapy,
will be included. In addition, we will explore viral and CD4 cell kinetics before starting
therapy and following exposure to antiretroviral agents.
The study will be conducted in three parts.
1. In order to help interpret the antiviral activity of indinavir, the virologic and
immunologic profile of children will be studied within 2 weeks prior to starting the
therapeutic part. For children who have never been treated, this will be before the
initiation of any antiretroviral therapy and for children who have already received
antiretroviral therapy, this will be done during the initial "wash-out" phase that is
routinely interposed between two different treatment regimens.
2. The initial 16 weeks of therapy will then evaluate the toxicities, pharmacokinetics,
and preliminary efficacy of single drug therapy with indinavir.
3. Subsequently, all children who are able to tolerate the combination of zidovudine and
lamivudine (i.e., have no prior history of intolerance to one of these two agents) will
be treated with these two reverse transcriptase inhibitors in addition to the protease
inhibitor indinavir. Zidovudine and lamivudine will be added after 16 weeks at a fixed
dosage. Toxicity, pharmacokinetics, and preliminary efficacy of indinavir will also be
investigated after combination therapy. All patients who wish to remain in this study
after 96 weeks of therapy and who do not meet off study criteria will be permitted to
receive extended treatment with their current indinavir combination therapy for an
additional 48 weeks.
The study will determine the pharmacokinetic profile of indinavir, given as single drug or
in combination with zidovudine and lamivudine. It will assess the preliminary antiviral and
clinical activity by monitoring clinical status, viral burden in plasma, and markers of
immunologic status. Based on safety and preliminary efficacy results from studies performed
in adults, we will study three dose levels which are expected to result in drug levels above
the IC95 of HIV-1 for all or most of the dosing interval.
Status | Completed |
Enrollment | 63 |
Est. completion date | October 2000 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Age - six months to 18 years. PREVIOUSLY UNTREATED OR MINIMALLY TREATED PATIENTS: Asymptomatic HIV-infected children with an age-corrected absolute CD4 count that renders them at possible risk for an AIDS-related opportunistic infection, or; Children with moderate to severe symptomatic HIV infection as defined by the CDC classification. Absence of active opportunistic infection requiring acute intervention at the time of entry. Prophylaxis for PCP with trimethoprim/sulfamethoxazole or pentamidine at the time of entry will be allowed. Availability of a parent or legal guardian to give informed consent and who is deemed sufficiently reliable to return for the child's follow-up visits. PREVIOUSLY TREATED PATIENTS WITH REFRACTORY DISEASE OR INTOLERANCE TO PRIOR THERAPY: HIV-infected patients who have been previously treated with one or more dideoxynucleosides (zidovudine, didanosine, lamivudine, stavudine, zalcitabine) or another protease inhibitor (will be analysed separately) and have experienced either a withdrawal grade toxicity or refractory disease evidenced by progressive clinical immunological deterioration. Availability of a parent or legal guardian to give informed consent and who is deemed sufficiently reliable to return for the child's follow-up visits. ALL CHILDREN: Must not be critically ill or clinically unstable. Patients receiving treatment for an acute infection must have been on stable therapy for at least 7 days prior to entry on study. MUST NOT HAVE ONE OR MORE OF THE FOLLOWING LABORATORY FINDINGS (WITHIN 2 WEEKS OF ENTRY AND NOT YET RESOLVED): Total WBC count less than 1500 cells/mm(3). Neutrophil plus band count less than 750 cells/mm(3). Hemoglobin less than 8.0 g/dl (history of recent transfusion is not an exclusion). Platelet count less than 500,000/mm(3). Creatinine greater than 2 times the upper limit of normal. Liver transaminase greater than 3 times the upper limit of normal. Bilirubin greater than 1.5 mg/dL. Hematuria. Because of the possibility for an increased risk of kidney stone formation patients must not have severe recurrent or persistent diarrhea, or a family history of kidney stones. Patients must not have received, within 30 days prior to entry, therapy with immunomodulating agents (interleukin-2, interferons, growth hormone, IGF-1, or other biological response modifier), cytolytic chemotherapeutic agents, radiation therapy. Stable (e.g., for greater than 4 weeks prior to entry) corticosteroids therapy for the treatment of lymphocytic interstitial pneumonitis or an autoimmune process or stable therapy with G-CSF (Neupogen) at the same dosage for at least 4 weeks are acceptable. Must not have an active opportunistic infection requiring acute intervention. Women must not be pregnant or breast feeding. |
Endpoint Classification: Safety Study, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | National Cancer Institute (NCI) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995 Jan 27;267(5197):483-9. — View Citation
Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM, Sigal IS. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4686-90. — View Citation
Pizzo PA, Eddy J, Falloon J, Balis FM, Murphy RF, Moss H, Wolters P, Brouwers P, Jarosinski P, Rubin M, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med. 1988 Oct 6;319(14):889-96. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |